(–)-CP 55,940

(–)-CP 55,940

CAT N°: 90084
Price:

From €176.00 €149.60

(?)-CP 55,940 is a potent and non-selective cannabinoid (CB) receptor agonist with Ki values of 0.5 to 5 and 0.69 to 2.8 nM for CB1 and CB2 receptors, respectively.{7912} It is more potent than ?9-THC (Item Nos. 12068 | ISO60157) in both behavioral tests and in receptor binding assays.{14402} In vivo, (?)-CP 55,940 administered intraperitoneally (0.3-3 mg/kg) or as an aerosol (0.72-72 mg/ml), suppresses locomotor activity, increases tail flick latency in a hot plate test for analgesia, and decreases body temperature in mice in a dose-dependent manner.{40291} Subchronic administration of (?)-CP 55,940 (0.03 mg/kg) also reduces body weight loss and running wheel activity in a rat model of anorexia nervosa.{40292}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 5-(1,1-dimethylheptyl)-2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-phenol
  • Correlated keywords
    • 55940p55940 cp55,940
  • Product Overview:
    (?)-CP 55,940 is a potent and non-selective cannabinoid (CB) receptor agonist with Ki values of 0.5 to 5 and 0.69 to 2.8 nM for CB1 and CB2 receptors, respectively.{7912} It is more potent than ?9-THC (Item Nos. 12068 | ISO60157) in both behavioral tests and in receptor binding assays.{14402} In vivo, (?)-CP 55,940 administered intraperitoneally (0.3-3 mg/kg) or as an aerosol (0.72-72 mg/ml), suppresses locomotor activity, increases tail flick latency in a hot plate test for analgesia, and decreases body temperature in mice in a dose-dependent manner.{40291} Subchronic administration of (?)-CP 55,940 (0.03 mg/kg) also reduces body weight loss and running wheel activity in a rat model of anorexia nervosa.{40292}

We also advise you

Any project? Any challenge? We are in!
Contact us

Headquarters:
Parc d’activités du Pas du Lac
10 bis avenue Ampère

78180 Montigny le Bretonneux
France

Call us
Information
My account
Follow us

Copyright © 2024 BERTIN BIOREAGENT. All rights reserved | Terms & conditions

Secure payment
Subscribe to our newsletter